company background image
ILMN logo

Illumina NasdaqGS:ILMN Stock Report

Last Price

US$137.32

Market Cap

US$22.0b

7D

-0.09%

1Y

-39.0%

Updated

28 Mar, 2024

Data

Company Financials +

ILMN Stock Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.

ILMN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for ILMN from our risk checks.

Illumina, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$137.32
52 Week HighUS$233.42
52 Week LowUS$89.00
Beta1.19
1 Month Change-1.75%
3 Month Change-1.38%
1 Year Change-39.04%
3 Year Change-64.34%
5 Year Change-56.41%
Change since IPO601.12%

Recent News & Updates

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20
Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Recent updates

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20
Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21
Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03
Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03
Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22
At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

The Big Trends: New Frontiers in Healthcare

Jul 13
The Big Trends: New Frontiers in Healthcare

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13
Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12
Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14
Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Dec 30
Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Dec 02
Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Oct 27
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB

Oct 18

Illumina in research collaboration with AstraZeneca on drug target discovery

Oct 11

Illumina Engages Obama To Push Its Customers' Reimbursement Agenda

Sep 29

Illumina to appeal EU decision to block GRAIL acquisition

Sep 06

Illumina Needs Grail, But May Lose It

Aug 30

Illumina added to positive catalyst watch at Citi despite Q2 miss

Aug 22

Illumina up 9% following drop after Q2 earnings

Aug 15

Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Aug 08
Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Still Avoiding Illumina Stock

Aug 05

Illumina, Grail deal unlikely to get EU nod – Reuters

Jul 27

Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?

Jul 22
Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?

Ensemble Capital Management - Illumina: Never Been So Cheap

Jul 19

Shareholder Returns

ILMNUS Life SciencesUS Market
7D-0.09%-0.2%0.4%
1Y-39.0%4.5%28.8%

Return vs Industry: ILMN underperformed the US Life Sciences industry which returned 4.5% over the past year.

Return vs Market: ILMN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement5.2%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ILMN has not had significant price volatility in the past 3 months.

Volatility Over Time: ILMN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199810,615Jacob Thaysenhttps://www.illumina.com

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILMN fundamental statistics
Market capUS$22.04b
Earnings (TTM)-US$1.16b
Revenue (TTM)US$4.50b

4.8x

P/S Ratio

-18.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ILMN income statement (TTM)
RevenueUS$4.50b
Cost of RevenueUS$1.56b
Gross ProfitUS$2.94b
Other ExpensesUS$4.10b
Earnings-US$1.16b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-7.31
Gross Margin65.30%
Net Profit Margin-25.78%
Debt/Equity Ratio25.9%

How did ILMN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.